Oregon Public Employees Retirement Fund Reduces Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Oregon Public Employees Retirement Fund decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 14.6% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,910 shares of the company’s stock after selling 840 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Medpace were worth $2,022,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Westwind Capital grew its holdings in Medpace by 800.1% during the 2nd quarter. Westwind Capital now owns 380,929 shares of the company’s stock valued at $156,886,000 after purchasing an additional 338,610 shares during the last quarter. TD Asset Management Inc boosted its position in shares of Medpace by 195.2% during the fourth quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after buying an additional 308,816 shares during the period. Findlay Park Partners LLP bought a new position in shares of Medpace during the first quarter valued at approximately $90,247,000. Clearbridge Investments LLC grew its stake in shares of Medpace by 302.4% during the first quarter. Clearbridge Investments LLC now owns 260,411 shares of the company’s stock valued at $105,245,000 after buying an additional 195,698 shares during the last quarter. Finally, Norges Bank purchased a new stake in shares of Medpace in the fourth quarter worth approximately $59,163,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $335.74 on Friday. The firm has a 50-day simple moving average of $390.71 and a 200-day simple moving average of $395.32. Medpace Holdings, Inc. has a one year low of $227.21 and a one year high of $459.77. The firm has a market cap of $10.40 billion, a P/E ratio of 34.22, a P/E/G ratio of 1.85 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last posted its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share for the quarter, topping analysts’ consensus estimates of $2.54 by $0.21. Medpace had a return on equity of 55.14% and a net margin of 16.74%. The company had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. During the same quarter in the prior year, the business earned $1.93 earnings per share. Medpace’s revenue was up 14.6% on a year-over-year basis. On average, research analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on MEDP. TD Cowen dropped their price objective on Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. William Blair restated an “outperform” rating on shares of Medpace in a report on Tuesday, July 23rd. Mizuho initiated coverage on shares of Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 price objective for the company. Robert W. Baird lowered their price objective on shares of Medpace from $469.00 to $430.00 and set an “outperform” rating for the company in a research report on Wednesday, July 24th. Finally, Guggenheim reduced their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating on the stock in a research report on Wednesday, July 24th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $423.00.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.